Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson’s Disease Conference

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson’s Disease Conference
BOSTON and ATLANTA, Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other ... read more
Source: PR NewswirePublished on 2022-09-21